Currently Enrolling

This is a Phase 2 clinical trial study of investigational drug XT-150 in participants experiencing moderate to severe pain due to osteoarthritis of the knee. XT-150 is a plasmid DNA that will be injected into the intra-articular space of the affected knee and has been shown to reduce inflammation through cytokine IL-10. The possible benefits of this clinical study include increased mobility following a single dose, reduction in the requirement for pain medications/therapies, and reduction in pain symptoms. This study involves a total of 15 visits at our site over the course of 1 year, and includes a stipend for each visit.

See if you’re eligible: Xalud Knee OA Pre-Screening

Learn more about this study »

This is a Phase 3 clinical trial study of investigational drug TG-C in participants living with chronic knee osteoarthritis. TG-C is to be administered by a single intra-articular injection to the damaged joint area. Patients will be followed for 24 months for safety and efficacy. Possible benefits include delayed progression of knee OA, longer knee joint preservation, and improved quality of life. The study will include follow-up visits over the course of 24 months, and includes a stipend for each visit.

See if you’re eligible: TissueGene Knee OA Pre-Screening

Learn more about this study »

**Although the study is on hold, do not hesitate to fill out the screening survey! We will contact you with updates about when the study will start up.

This is a Phase 3 clinical trial study of investigational drug SI-6003 (Condoliase) in participants with lumbar disc herniation. SI-6003 is a single intradiscal treatment injection to the herniated disc. Potential benefits include reduced leg pain, reduced low back pain, and/or improved numbness of associated extremities. This study will include follow-up visits over the course of 13 months, and includes a stipend for each visit.

See if you’re eligible: SKK Disc Herniation Pre-Screening

Learn more about this study »